Outcomes of HER2-positive nonmetastatic breast cancer patients with or without deleterious BRCA mutations after trastuzumab treatment. This is an ASCO Meeting Abstract from the 2013 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback